|
|
|||||||||||||||||||||||||||
|
MyoKardia Inc (MYOK) MyoKardia is a clinical-stage biopharmaceutical company. Co.'s initial research has focused on genetic mutations in sarcomeric proteins of the heart muscle. Co.'s primary therapeutic candidate, mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). In addition to mavacamten, Co.'s programs include Danicamtiv, an orally-administered small molecule designed to increase cardiac contractility without impairing diastolic filling in patients with systolic heart failure; and MYK-224, a small molecule program for the treatment of HCM targeting hypercontractility and impaired relaxation.
|
|
|||||||||||||||||||||||||||
Free MYOK Email Alerts:
MyoKardia Inc (MYOK) Page | The Online Investor | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.